These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24202729)

  • 1. CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
    Moon CH; Lee SJ; Lee HY; Dung le TK; Cho WJ; Cha H; Park JW; Min YJ
    Invest New Drugs; 2014 Jun; 32(3):400-11. PubMed ID: 24202729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer.
    Kim SJ; Jegal KH; Im JH; Park G; Kim S; Jeong HG; Cho IJ; Kang KW
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):685-697. PubMed ID: 32157413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.
    Kim KW; Lee JM; Jeon YS; Lee IJ; Choi Y; Park J; Kiefer B; Kim C; Han JK; Choi BI
    Invest New Drugs; 2013 Oct; 31(5):1097-106. PubMed ID: 23299389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced efficacy of CKD-516 in combination with doxorubicin: pre-clinical evaluation using a hepatocellular carcinoma xenograft model.
    Kim YI; Kim KW; Lee HK; Park J; Chung JW; Youn H; Kim SJ; Kim DH; Tseng JC; Lee JM
    Anticancer Res; 2014 Apr; 34(4):1715-22. PubMed ID: 24692701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.
    Moon CH; Lee SJ; Lee HY; Lee JC; Cha H; Cho WJ; Park JW; Park HJ; Seo J; Lee YH; Song HT; Min YJ
    PLoS One; 2013; 8(1):e53900. PubMed ID: 23326531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma.
    Kim MY; Shin JY; Kim JO; Son KH; Kim YS; Jung CK; Kang JH
    BMC Cancer; 2020 Nov; 20(1):1057. PubMed ID: 33143663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.
    Galmarini CM; Martin M; Bouchet BP; Guillen-Navarro MJ; Martínez-Diez M; Martinez-Leal JF; Akhmanova A; Aviles P
    BMC Cancer; 2018 Feb; 18(1):164. PubMed ID: 29415678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
    Gardner ER; Kelly M; Springman E; Lee KJ; Li H; Moore W; Figg WD
    Invest New Drugs; 2012 Feb; 30(1):90-7. PubMed ID: 20820910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).
    Cai YC; Zou Y; Ye YL; Sun HY; Su QG; Wang ZX; Zeng ZL; Xian LJ
    Invest New Drugs; 2011 Apr; 29(2):300-11. PubMed ID: 20012336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma.
    Yang M; Su Y; Wang Z; Du D; Wei S; Liao Z; Zhang Q; Zhao L; Zhang X; Han L; Jiang J; Zhan M; Sun L; Yuan S; Zhou Z
    Biochem Pharmacol; 2021 Aug; 190():114641. PubMed ID: 34077738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
    Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
    Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA-1H, a novel oxazole bearing analogue of combretastatin A-4, disrupts the tumor vasculatures and inhibits the tumor growth via inhibiting tubulin polymerization.
    Han F; Wang P; Zhang W; Li J; Zhang Q; Qi X; Liu M
    Biomed Pharmacother; 2016 May; 80():151-161. PubMed ID: 27133052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.
    Lee J; Kim SJ; Choi H; Kim YH; Lim IT; Yang HM; Lee CS; Kang HR; Ahn SK; Moon SK; Kim DH; Lee S; Choi NS; Lee KJ
    J Med Chem; 2010 Sep; 53(17):6337-54. PubMed ID: 20690624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model.
    Zhou S; Yang Y; Yang Y; Tao H; Li D; Zhang J; Jiang G; Fang J
    PLoS One; 2013; 8(7):e68589. PubMed ID: 23874680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent.
    Rickardson L; Kutvonen E; Orasniemi S; Högberg M; Kallio MJ; Rehnmark S
    Drug Des Devel Ther; 2017; 11():1335-1351. PubMed ID: 28496304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
    Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural product derivative Bis(4-fluorobenzyl)trisulfide inhibits tumor growth by modification of beta-tubulin at Cys 12 and suppression of microtubule dynamics.
    Xu W; Xi B; Wu J; An H; Zhu J; Abassi Y; Feinstein SC; Gaylord M; Geng B; Yan H; Fan W; Sui M; Wang X; Xu X
    Mol Cancer Ther; 2009 Dec; 8(12):3318-30. PubMed ID: 19996274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of tubulin binding cofactor C modifies microtubule dynamics and cell cycle distribution and enhances sensitivity to gemcitabine in breast cancer cells.
    Hage-Sleiman R; Herveau S; Matera EL; Laurier JF; Dumontet C
    Mol Cancer Ther; 2011 Feb; 10(2):303-12. PubMed ID: 21216936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
    Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.